プレマーケット: .35 -0.007 -1.96%

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc (PTPI) 最新ニュース

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc (PTPI) 最新ニュース

Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com

Petros Pharmaceuticals reports high comprehension in drug app study - Investing.com

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - StockTitan

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

A History of Outperforming Analyst Forecasts and Beating the Odds: Petros Pharmaceuticals Inc (PTPI) - SETE News

Analytical Overview: Petros Pharmaceuticals Inc (PTPI)’s Ratios Tell a Financial Story - The Dwinnex

A stock that deserves closer examination: Petros Pharmaceuticals Inc (PTPI) - US Post News

Petros Pharmaceuticals stock hits 52-week low at $0.28 - Investing.com India

Petros Pharmaceuticals stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada

Petros Pharmaceuticals stock hits 52-week low at $0.28 - Investing.com

Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 - MSN

Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4% - Defense World

Petros Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com

Joel Baglole - InvestorPlace

Closing Figures: Petros Pharmaceuticals Inc (PTPI)’s Negative Finish at 0.41, Down -3.55 - The Dwinnex

Petros Pharmaceuticals reports promising Web App study - Investing.com

PTPI’s Market Whiplash: -70.74% YTD Decline, -7.41% Plunge in 30 Days - The InvestChronicle

Petros Pharmaceuticals reports promising Web App study - Investing.com India

Petros Pharmaceuticals Inc (NASDAQ:PTPI) stock: Is this a flash in the pan today? - US Post News

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - StockTitan

Petros Pharma (NASDAQ:PTPI) Stock Quotes, Forecast and News Summary - Benzinga

Get in on Petros Pharmaceuticals Inc’s (PTPI) buy-in window today! - SETE News

Financial Metrics Exploration: Understanding Petros Pharmaceuticals Inc (PTPI) Through Ratios - The Dwinnex

Petros reports successful study for STENDRA OTC switch By Investing.com - Investing.com Canada

Petros Pharmaceuticals Inc Inc. (PTPI) Price Performance: A Technical Analysis Perspective - The InvestChronicle

Petros reports successful study for STENDRA OTC switch - Investing.com

Petros reports successful study for STENDRA OTC switch - Investing.com India

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - AccessWire

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - StockTitan

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - Yahoo Finance

Quarterly Metrics: Quick and Current Ratios for Petros Pharmaceuticals Inc (PTPI) – DWinneX - The Dwinnex

Can you still get a good price for Petros Pharmaceuticals Inc (PTPI) Shares at this point? - US Post News

Pioneering change: male contraceptives and the coming OTC revolution - Interesting Engineering

The future of health: male contraceptives and OTC innovation - Interesting Engineering

PTPI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Petros Pharmaceuticals Inc (PTPI)'s Market Momentum: Closing Strong at 0.41, Down -2.50 – DWinneX - The Dwinnex

Petros Pharmaceuticals Inc (PTPI) did well last session? – US Post News - US Post News

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros ... - AOL

'The Prescription Erectile Dysfunction Market Could Triple if an ED Therapy Becomes Available - The Bharat Express News

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros ... - TradingView

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says - Yahoo Finance

Stock Surge: Petros Pharmaceuticals Inc (PTPI) Closes at 0.46, Marking a -13.70 Increase/Decrease – DWinneX - The Dwinnex

Healthy Upside Potential: Petros Pharmaceuticals Inc (PTPI) – Sete News - SETE News

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketBroadcom (NASDAQ ... - Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace

COMPASS Pathways (NASDAQ:CMPS) & Petros Pharmaceuticals (NASDAQ:PTPI) Critical Contrast - Defense World

Trading Day Review: Petros Pharmaceuticals Inc (PTPI) Gains Momentum, Closing at 0.62 - The Dwinnex

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive ... - Yahoo Finance

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch - AccessWire

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA - Yahoo Finance

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 - InvestorPlace

Petros Pharmaceuticals teams up with Lemonaid Health for ED treatment access - Investing.com

Petros Pharmaceuticals teams up with Lemonaid Health for ED treatment access - Investing.com India

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently ... - Yahoo Finance

Lemonaid Health Now Offers Prescription ED Medication STENDRAR Through Collaboration with Petros ... - GlobeNewswire

Lemonaid Health Now Offers Prescription ED Medication STENDRAR Through Collaboration with Petros ... - Yahoo Finance

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals - Yahoo Finance

Panbela Therapeutics (PBLA) Stock Forecast and Price Target 2024 - MarketBeat

Rx Rundown: Xaira Therapeutics, Ipsen, Sanofi and more - MM+M Online

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health - Yahoo Finance

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health - Proactive Investors Australia

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health | NASDAQ:PTPI - Proactive Investors USA

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health - AccessWire

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - Yahoo Finance

Birth Control Market Evolves as OTC Opill Hits US Stores - BioSpace

Petros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations - Simply Wall St

PTPIに似た銘柄